JP2019504064A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504064A5
JP2019504064A5 JP2018535391A JP2018535391A JP2019504064A5 JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5 JP 2018535391 A JP2018535391 A JP 2018535391A JP 2018535391 A JP2018535391 A JP 2018535391A JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504064A (ja
Filing date
Publication date
Priority claimed from PCT/US2016/052014 external-priority patent/WO2017049011A1/en
Application filed filed Critical
Priority claimed from PCT/US2017/012606 external-priority patent/WO2017120523A2/en
Publication of JP2019504064A publication Critical patent/JP2019504064A/ja
Publication of JP2019504064A5 publication Critical patent/JP2019504064A5/ja
Priority to JP2022185469A priority Critical patent/JP7723649B2/ja
Priority to JP2025128180A priority patent/JP2025170265A/ja
Pending legal-status Critical Current

Links

JP2018535391A 2016-01-08 2017-01-06 抗プロ/潜在型ミオスタチン抗体およびその使用方法 Pending JP2019504064A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022185469A JP7723649B2 (ja) 2016-01-08 2022-11-21 抗プロ/潜在型ミオスタチン抗体およびその使用方法
JP2025128180A JP2025170265A (ja) 2016-01-08 2025-07-31 抗プロ/潜在型ミオスタチン抗体およびその使用方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662276698P 2016-01-08 2016-01-08
US62/276,698 2016-01-08
US201662328597P 2016-04-27 2016-04-27
US62/328,597 2016-04-27
US201662333816P 2016-05-09 2016-05-09
US201662333810P 2016-05-09 2016-05-09
US62/333,810 2016-05-09
US62/333,816 2016-05-09
PCT/US2016/052014 WO2017049011A1 (en) 2015-09-15 2016-09-15 Anti-pro/latent-myostatin antibodies and uses thereof
USPCT/US2016/052014 2016-09-15
US201662413278P 2016-10-26 2016-10-26
US62/413,278 2016-10-26
PCT/US2017/012606 WO2017120523A2 (en) 2016-01-08 2017-01-06 Anti-pro/latent myostatin antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022185469A Division JP7723649B2 (ja) 2016-01-08 2022-11-21 抗プロ/潜在型ミオスタチン抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019504064A JP2019504064A (ja) 2019-02-14
JP2019504064A5 true JP2019504064A5 (cg-RX-API-DMAC10.html) 2020-03-12

Family

ID=59274466

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535391A Pending JP2019504064A (ja) 2016-01-08 2017-01-06 抗プロ/潜在型ミオスタチン抗体およびその使用方法
JP2022185469A Active JP7723649B2 (ja) 2016-01-08 2022-11-21 抗プロ/潜在型ミオスタチン抗体およびその使用方法
JP2025128180A Pending JP2025170265A (ja) 2016-01-08 2025-07-31 抗プロ/潜在型ミオスタチン抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022185469A Active JP7723649B2 (ja) 2016-01-08 2022-11-21 抗プロ/潜在型ミオスタチン抗体およびその使用方法
JP2025128180A Pending JP2025170265A (ja) 2016-01-08 2025-07-31 抗プロ/潜在型ミオスタチン抗体およびその使用方法

Country Status (9)

Country Link
US (4) US10287345B2 (cg-RX-API-DMAC10.html)
EP (1) EP3400240A2 (cg-RX-API-DMAC10.html)
JP (3) JP2019504064A (cg-RX-API-DMAC10.html)
KR (1) KR20180094110A (cg-RX-API-DMAC10.html)
CN (2) CN115814077A (cg-RX-API-DMAC10.html)
AU (2) AU2017206069A1 (cg-RX-API-DMAC10.html)
MX (3) MX2018008369A (cg-RX-API-DMAC10.html)
SG (1) SG11201805709RA (cg-RX-API-DMAC10.html)
WO (1) WO2017120523A2 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN115814077A (zh) * 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
DK3768320T3 (da) * 2018-03-23 2026-08-10 Cytoo Kombination af alk5-hæmmere og glukokortikoider som induktorer af skeletmuskelhypertrofi
EP3807288A1 (en) * 2018-05-24 2021-04-21 Valkyrie Pharmaceutics, Inc. Methods and formulations for the treatment of obesity and obesity-related metabolic diseases
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
US11455381B2 (en) 2020-04-21 2022-09-27 CIELO Enterprise Solutions, Inc. Systems and methods for providing multiple functionalities associated with a QR code
CR20220598A (es) * 2020-04-30 2023-01-17 Genentech Inc Anticuerpos específicos para kras y sus usos
DK4358995T3 (da) 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
EP4426306A1 (en) * 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2026147753A1 (en) 2024-12-30 2026-07-09 Scholar Rock, Inc. Therapies for muscular dystrophies

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
PL357017A1 (en) 2000-01-28 2004-07-12 Novo Nordisk A/S Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
ATE364632T1 (de) 2001-10-05 2007-07-15 Affimed Therapeutics Ag Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
AU2003267246A1 (en) 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2005066204A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
CA2558478A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1755648A2 (en) 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
US7888486B2 (en) * 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) * 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
BRPI0715072A2 (pt) 2006-08-03 2013-06-25 Orico Ltd antagonistas de miostatina
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
WO2008067480A2 (en) 2006-11-29 2008-06-05 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
JP2010519256A (ja) 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、HLA−E/Qa−1拘束性CD8+T細胞制御性経路を活性化または遮断する方法
KR101531722B1 (ko) 2007-03-30 2015-06-25 메르크 파텐트 게엠베하 음성 광학 분산도를 갖는 복굴절층
AU2008260445A1 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US8952130B2 (en) 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
US8945511B2 (en) 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
NZ599604A (en) 2009-10-01 2014-07-25 Myostin Therapeutics Pty Ltd Synthetic myostatin peptide antagonists
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
PH12013500315A1 (en) * 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
HRP20201914T1 (hr) * 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina

Similar Documents

Publication Publication Date Title
Reichenbach et al. Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model
Zhou et al. Cytokine signaling in skeletal muscle wasting
JP2018535948A5 (cg-RX-API-DMAC10.html)
CN106068125B (zh) 治疗脂肪组织积聚的组合物和方法
JP2015506944A5 (cg-RX-API-DMAC10.html)
JP2016536332A5 (cg-RX-API-DMAC10.html)
JP2013165711A5 (cg-RX-API-DMAC10.html)
WO2008050329A3 (en) Novel sirnas and methods of use thereof
US20260035448A1 (en) Selective and potent inhibitory antibodies of myostatin activation
WO2017120523A4 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
JP2010520290A5 (cg-RX-API-DMAC10.html)
US11786585B2 (en) Anti-IGFBP-3R antibodies and methods of treating an IGFBP-3R expressing cancer
FI3565592T3 (fi) Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
US20130344081A1 (en) Method of treating amyotrophic lateral sclerosis
CN108431039B (zh) 改进的p2x7受体结合剂和包含其的多肽
CA3028586A1 (en) Wnt inhibitors for use in the treatment of fibrosis
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
JP2008540457A (ja) 心臓血管疾患の治療
US12098129B2 (en) Pharmaceutical composition for treating fibrosis
JP2023510854A5 (cg-RX-API-DMAC10.html)
Angelino et al. Antifibrotic activity of acylated and unacylated ghrelin
JP2023500492A5 (cg-RX-API-DMAC10.html)
JP2023544620A5 (cg-RX-API-DMAC10.html)
WO2018130513A1 (en) Use of cd47 antibodies
TW201945026A (zh) 結合erfe之抗體及使用方法